Chill Brands Group PLC

Chill Brands Group PLC, established in 2014, operates from its headquarters in London, United Kingdom. The company focuses on the innovation, manufacturing, and distribution of cannabidiol (CBD) consumer items and other lifestyle products across the United States and the United Kingdom. Its product range includes alternatives to tobacco, such as smokable items and chewable pouches. Additionally, the company provides a variety of CBD-infused goods, including oral tinctures, soft-gel capsules, massage oils, and cosmetic products for topical application. In August 2021, the entity formerly known as Zoetic International Plc officially adopted its current name, Chill Brands Group PLC.

Chill Brands Group PLC trades as CHLL.L on LSE. The company is classified in Healthcare / Drug Manufacturers - Specialty & Generic and reports in GBP.

The current profile places the business in Drug Manufacturers - Specialty & Generic. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows £370,501 of revenue and -£2.88M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Chill Brands Group PLC can be compared against peers such as Cambridge Nutritional Sciences plc, CRISM Therapeutics Corporation, Genedrive Plc, MyHealthChecked PLC, N4 Pharma Plc, Oxford BioDynamics Plc.

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of £15,688, beta of -0.18, and return on equity of +233.8%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

CHLL.L currently shows total debt of £2.66M and beta of -0.18. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://chillbrandsgroup.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.